Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.49 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.49 |
| ▸ | SCD | O00767 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1181660 | 0.92 | SIRT5 (0.47) | MAPTSIRT5SERPINE1SCDMEN1 | |
| SCHEMBL1182126 | 0.89 | SIRT5 (0.50) | MAPTSIRT5SERPINE1SCDMEN1 | |
| SCHEMBL1181638 | 0.88 | SIRT5 (0.45) | MAPTSIRT5SERPINE1SCDMEN1 | |
| SCHEMBL1182094 | 0.88 | MAPT (0.52) | MAPTSIRT5SERPINE1SCDAURKA | |
| SCHEMBL1182286 | 0.87 | MAPT (0.56) | MAPTSIRT5SCDMEN1KMT2A | |
| SCHEMBL906583 | 0.86 | MAPT (0.55) | MAPTSIRT5SCDKMT2AATG4B | |
| SCHEMBL1182738 | 0.84 | SCD (0.48) | MAPTSIRT5SERPINE1SCDRPS6KB1 | |
| SCHEMBL1182282 | 0.82 | SIRT5 (0.44) | MAPTSIRT5SERPINE1MEN1KMT2A | |
| SCHEMBL1183047 | 0.81 | SIRT5 (0.52) | MAPTSIRT5MEN1KMT2AALDH1A1 | |
| SCHEMBL906408 | 0.81 | MAPT (0.49) | MAPTSIRT5SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148376-B2 | 3, 4-dihydroquinoxalin-2(1H)-ones for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-7893066-B2 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100204238-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-7732453-B2 | Pyrido[2,3-B] pyrazin-3(4H)-ones for use as stearoyl CoA desaturase inhibitors | GILEAD PALO ALTO, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| CN-101522676-A | Bicyclic nitrogen-containing heterocyclic compounds as stearoyl-CoA dehydrogenase inhibitors | CV THERAPEUTICS INC (US) | 2009-09-02 | — | — | CN | disclosed |
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080139570-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204238-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | MAPT 3727/4885SIRT5 334/4885SERPINE1 3773/4885 |
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | SCD, SCD5, FASN | MAPT 4376/4885SIRT5 382/4885SERPINE1 3914/4885 |
| US-20080139570-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | MAPT 3727/4885SIRT5 334/4885SERPINE1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.